Navigation Links
SCOLR Pharma, Inc. Announces Second Quarter 2011 Financial Results
Date:7/26/2011

x months ended June 30, 2011, compared to $389,000 for the same period in 2010. This decrease is due to a $190,000 reduction in royalty revenue from sales of nutritional products by Perrigo compared to the prior period. The Company recognized $100,000 in research and development revenue attributable to a contract with RedHill Biopharma Ltd. for certain development services in connection with the license by RedHill of SCOLR's CDT platforms for use in Ondansetron tablet formulations, as well as an $18,000 research and development from Syntrix Biopharma.

Marketing and selling expenses increased 23%, or $33,000, to $178,000 for the six months ended June 30, 2011, compared to $145,000 for the same period in 2010. This increase was primarily due to marketing and sales brokerage related expenses and the addition of a sales and marketing staff person anticipated to assist with advancement of our of nutritional products business.

Research and development expenses decreased 9%, or $52,000, to $544,000 for the six months ended June 30, 2011, compared to $596,000 for the same period in 2010. This decrease is due to the gain on sale of lab equipment of $120,000, reduction in personnel, and the reduction in operating expenses as a result of the elimination of lab activities.

General and administrative expenses increased 13%, or $152,000, to $1.3 million for the six months ended June 30, 2011, compared to approximately $1.2 million for the same period in 2010, primarily due to recognition of $61,000 in accelerated depreciation expense as a result of the reduction in the term of our headquarters lease. In addition, legal expenses increased $48,000.

Other income increased $101,000 to $94,000 for the six months ended June 30, 2011, compared to an expense of $7,000 for the comparable period in 2010. This increase is due to a change of $90,000 in unrealized gain on fair value of warrant to purchase common stock for the six months ended June 30, 2011 as comp
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. SCOLR Pharma, Inc. First Quarter 2011 Financial Results
2. SCOLR Pharma, Inc. to Present at Taglich Brothers 8th Annual Small Cap Equity Conference
3. SCOLR Pharma, Inc. Reports 2010 Financial Results, Provides Updates on Advances in Nutritionals, OTC Drugs
4. SCOLR Pharma, Inc. Receives Deficiency Letter from FDA on Pseudoephedrine Application
5. SCOLR Pharma, Inc. Retains Nicholas Hall & Company
6. SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
7. SCOLR Pharma, Inc. Announces Intention to Voluntarily Delist From NYSE AMEX Exchange
8. SCOLR Pharma, Inc. Reports Third Quarter 2010 Financial Results
9. SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director
10. SCOLR Pharma, Inc. Signs Agreement with The Emerson Group to Provide Sales Support for Nutritional & OTC Products
11. SCOLR Pharma, Inc. Enters into Worldwide Licensing Agreement with RedHill Biopharma Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 According to ... "Orthopedic Trauma Fixation Devices Market - Global Forecast, Market ... the global orthopedic trauma fixation devices market is estimated ... to grow at a CAGR of 7.2% from 2014 ... 9.3 billion in 2020. Browse the Orthopedic ...
(Date:7/29/2014)... , July 29, 2014  Instrumentation Laboratory (IL) today announced ... new corporate logo. This is part of a comprehensive rebranding ... Founded in Boston, MA , in 1959, ... companies since 1992.  Other companies in the group include Inova ... Systelab ( Barcelona, Spain ).  Like IL, these ...
(Date:7/29/2014)... DUBLIN , July 29, 2014 ... the "Global Respiratory Devices Market 2014-2018" report ... A respiratory device is a medical ... who is having difficulty in breathing and cannot achieve ... disorders such as cystic fibrosis, asthma, COPD, and ARDS ...
Breaking Medicine Technology:Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 2Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 3Orthopedic Trauma Fixation Devices Market is Expected to Reach USD 9.3 Billion Globally in 2020: Transparency Market Research 4Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3Global Respiratory Devices Market 2014-2018 2
... MOSCOW, Jan. 3, 2012 Goodwin Biotechnology, Inc. (GBI) ... announced an agreement for cell line engineering and manufacturing ... line. The monoclonal antibody will be engineered by GBI,s ... lines, select the highest producer and manufacture the monoclonal ...
... 3, 2012 /PRNewswire-Asia/ -- The Ministry of Health and Welfare ... Kyung-Hwa) announced that a 19-year-old woman, Tan Hui-Linn, has been ... Korea project and will receive surgery at the JK Plastic ... life that was once full of hopes shattered on Oct. ...
Cached Medicine Technology:Goodwin Biotechnology and OncoMax, a Maxwell Biotech Portfolio Company, Announce a "Bench-to-Clinic" Collaboration for an Important Advance in Oncology 2Goodwin Biotechnology and OncoMax, a Maxwell Biotech Portfolio Company, Announce a "Bench-to-Clinic" Collaboration for an Important Advance in Oncology 3Acid Attack Victim from Malaysia Restores Her Lost Face with Support of Medical Korea 2
(Date:7/30/2014)... According to the Yeast Infection No More book review ... will help candida sufferers get rid of their yeast ... to readers the truth about yeast infection and the real ... will discover natural and safe remedies to relieve symptoms of ... irritation of the vagina or vulva. , Vkool reveals ...
(Date:7/30/2014)... Seattle, WA (PRWEB) July 30, 2014 According ... by Vkool.com, this is a comprehensive bodybuilding guide for men ... press by up to 50 pounds in within a ... routine that will help keep their shoulders healthy and avoid ... that the Critical Bench Program 2.0 uncovers to learners the ...
(Date:7/30/2014)... Kennewick, WA (PRWEB) July 30, 2014 ... today availability of over 80 different electronic therapy ... notes on tablets and other computing devices all ... 80+ therapy notes or electronic medial records (EMR) ... initial evaluations, and other essential categories. SOAP ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 pMD, ... physician communication, launched an Observation Result (ORU) interface ... hospital. pMD’s cardiology customers are using the ORU ... for their test interpretations for electrocardiograms, echocardiograms, and ... in the hospital, the cardiology system produces electronic ...
(Date:7/30/2014)... TN (PRWEB) July 30, 2014 Regents ... medical imaging services, has brought health care industry veteran ... on board to help lead the company’s ambitious plans ... , “Regents Health has been moving along at a ... to kick it up a notch,” says Bob Maier, ...
Breaking Medicine News(10 mins):Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 2Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 3Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 2Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 3Health News:My Clients Plus Announces Over 80 Online Therapy Notes to Help Healthcare Providers Go Paperless 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Sferrella and Demonbreun Join Regents Health Resources 2
... Nov. 27 S*BIO Pte Ltd today announced ... development,candidate, SB1317. This is a novel orally-available small ... SB1317 is designed to selectively inhibit major ... progression in acute,leukemias. Flt3 mutations are the most ...
... NEWTOWN SQUARE, Pa., Nov. 27 In its ... homeopathy, Boiron,Laboratories disputes an editorial comment published in ... that its author has misinterpreted results of,clinical trials ... journal features an editorial by Ben Goldacre on,the ...
... reflect reports of bizarre behaviors and sudden deaths ... U.S. Food and Drug Administration advisory panel recommended Tuesday ... a stronger warning label to reflect reports of bizarre ... , The FDA,s Pediatric Advisory Committee, in a 9-5 ...
... Nov. 27 Zimmer Holdings, Inc.,(NYSE: ZMH ; ... resign,as Chairman of the Board and a member of ... years of service with the Company. John L.,McGoldrick, a ... Mr. Elliott served as Chairman, President and Chief Executive ...
... Pronounced "mursa,",methicillin-resistant staphylococcus aureus (MRSA) is one of ... about it. It has,killed the elderly, babies, toddlers, teenagers ... closing public schools., One of the most common ... infection can start innocently, perhaps with a nick or ...
... 90%+ Success Rate..., CLEARWATER, Fla., Nov. 27 ... announced,today that it has certified over 600 surgeons in ... were trained in the basic technique at the,North American ... "We believe that this milestone is a reasonable ...
Cached Medicine News:Health News:S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias 2Health News:Boiron Laboratories Disputes British Journal's Editorial on Homeopathy 2Health News:Boiron Laboratories Disputes British Journal's Editorial on Homeopathy 3Health News:FDA Panel Backs Tougher Warning for Tamiflu 2Health News:FDA Panel Backs Tougher Warning for Tamiflu 3Health News:Ray Elliott to Retire as Chairman of Zimmer Holdings; John McGoldrick to Serve as Non-Executive Chairman 2Health News:Ray Elliott to Retire as Chairman of Zimmer Holdings; John McGoldrick to Serve as Non-Executive Chairman 3Health News:New Booklet Reveals 12 Proven Methods for Stopping MRSA from Infecting Your Feet and Your Family's Feet 2Health News:Over 600 Surgeons Certified to use TruFUSE(R) to Treat Back Pain Sufferers 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: